Trials / Completed
CompletedNCT03597295
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retifanlimab | Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W). |
Timeline
- Start date
- 2018-10-08
- Primary completion
- 2020-06-08
- Completion
- 2021-11-10
- First posted
- 2018-07-24
- Last updated
- 2025-08-21
- Results posted
- 2021-08-23
Locations
46 sites across 9 countries: United States, Belgium, Denmark, France, Germany, Italy, Norway, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03597295. Inclusion in this directory is not an endorsement.